XGN
$3.17
Exagen Inc.
Recent News
Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments
Exagen Inc (XGN) reports a near 20% revenue increase for 2025, driven by testing volume growth and strategic expansions, despite facing profitability challenges.
Exagen Q4 Earnings Call Highlights
Exagen (NASDAQ:XGN) executives said the company closed 2025 with record revenue and testing volume, pointing to progress from operational changes made over the past several years, while acknowledging near-term average selling price (ASP) pressure tied largely to a previously disclosed client billing
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
Exagen (XGN) delivered earnings and revenue surprises of 0.00% and +1.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
What Analysts Think Is Changing The Story For Exagen (XGN) Now
Why Exagen’s Fair Value Target Just Got Trimmed Analysts have recently reset their view on Exagen, with the fair value estimate moving from $14.71 to $13.29, a reduction of about 9.7%. At the same time, the discount rate in their models has shifted from 7.53% to 7.72% and revenue growth assumptions have moved only fractionally from 11.58% to 11.55%. This mix of a lower target price, a slightly higher required return, and largely unchanged growth expectations reflects a more cautious stance on...
How The Exagen (XGN) Story Is Shifting With A New Analyst Price Target
The change in price target for Exagen has put a spotlight on how analysts currently view the company and its risk reward profile. With no previous target or detailed commentary provided, the focus now shifts to what this fresh target implies for expectations around the stock. Stay tuned to see how you can keep on top of future updates as this narrative continues to take shape. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value...